Study Comparing the Efficacy and Safety of Insulin Glargine (Basal Insulin)/Lixisenatide (GLP-1 Receptor Agonist) Combination (Soliqua™) in Patients With Type 2 Diabetes Mellitus (T2DM)

NCT03767543 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

265

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: INSULIN GLARGINE/LIXISENATIDE HOE901/AVE0010

Sponsor

Sanofi